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Objective: The purpose of this study was to determine the differences in outcome related to initial management of aortic
endograft limb occlusion (ELO).
Methods: During a 7-year period, 823 endovascular aneurysm repairs (EVARs) resulted in 25 ELOs in 22 patients. The
initial management and outcome of these ELOs were reviewed. Median follow-up after ELO was 24.2  16.8months.
Results: Initial EVARs included both unsupported unibody (n  5) and supported modular (n  17) devices. ELO was
significantly more common in the unsupported unibody graft design (P < .024) and with extension of the graft limb to
the external iliac artery (P < .001). ELO was managed with an endovascular approach (EVA), including some
combination of mechanical thrombectomy (n 8), angioplasty with or without stenting (n 8), and thrombolysis (n
2) in 12 patients and bypass procedures (femoral-femoral bypass, n  11; axillofemoral bypass, n  1; and aortofemoral
bypass, n  1) in 13. At 12-month follow-up, freedom from secondary procedures with EVA was 80.2  17.7% versus
53.217.1% with extra-anatomic bypass (EB) (PNS). Secondary patency was 100% with EVA and 80.6 14.4% with
EB (P  NS). Of the 12 EVAs, there was 1 (8.3%) perioperative mortality with EVA and none with EB. EB failure was
directly attributed to donor limb occlusion in 4 of 6 EVAs (67%), and when this occurred it resulted in bilateral lower
extremity ischemia. Amputation was required in 2 of 12 (16.7%) EBs versus none of the 12 EVAs (P  NS). EVA never
resulted in graft dislodgement or endoleak but did identify an underlying treatable cause in 8 of 12 (67%).
Conclusion: Both EVA and EB are acceptable management strategies for ELO. The potential risk of graft dislodgement
was not observed with an EVA. If EB is employed, assessment of the donor limb and treatment of any underlying lesions
is advisable in an attempt to minimize future donor limb occlusion. (J Vasc Surg 2004;40:419-23.)Endovascular aneurysm repair (EVAR) has been in-
creasingly used to treat infrarenal aortic aneurysms. The
attractiveness of EVAR is largely based on its minimally
invasive nature. However, along with this advantage comes
the need for increased long-term surveillance because of
device-related complications and the potential requirement
for reintervention and even conversion to open aneurysm
repair. Specifically, a group of complications and adverse
events unique to the procedure such as endoleak, graft
migration, continued aneurysm expansion, and endograft
limb occlusion (ELO) have been identified.1
Limited experience and lack of long-term outcome
results makes determining an optimal treatment for these
complications difficult. ELO has been managed with a
variety of approaches; earlier experience tended toward
extra-anatomic bypass (EB) including femoral-femoral by-
pass.2,3 More recent case reports and series have encour-
aged an endovascular approach with or without thrombol-
ysis.4-7 The purpose of this study was to review a single
institution’s experience with ELO and determine differ-
ences in outcome related to initial management.
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Records of all patients undergoing EVAR at the Cleve-
land Clinic Foundation were reviewed to identify ELO. All
patients consented to participate in an institutional review
board approved vascular registry. Over a 7-year period
ending in March 2003, a total of 823 infrarenal aortic
aneurysms were repaired with EVAR. Devices commonly
used during this time included Ancure (Guidant, Menlo
Park, Calif), AneuRx (Medtronic/AVE, Santa Rosa, Calif),
Excluder (W.L. Gore, Flagstaff, Ariz), Zenith (Cook,
Bloomington, Ind), Quantum (Cordis, Warren, NJ) and
Talent (Medtronic, Sunrise, Fla).
Our follow-up protocol for EVAR has been previously
reported8 and includes history and physical, 4-view abdom-
inal films, and helical contrast computed tomography (CT)
scan preoperatively; at 1, 6, 12 months; and yearly thereaf-
ter. Patients developing ELO were identified with a com-
puterized vascular registry as well as review of all EVAR
patient records. Initial presentation, management, and out-
come of ELO were recorded.
Management of ELO was divided into 2 categories for
analysis. An endovascular approach (EVA) was defined as
any approach using catheter-based technology for restora-
tion of blood flow through the endograft limb itself. This
included balloon catheter thrombectomy, mechanical cath-
eter thrombectomy, angioplasty with or without stenting,
and thrombolysis. Bypass procedures (BPs) included any
revascularization that did not restore or attempt to restore
blood flow through the endograft itself. This included EBs419
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well as direct aortofemoral bypass.
Statistical analysis was performed using JMP statistical
software (Cary, NC). Kaplan-Meier life-table analysis was
used to express freedom from secondary procedures and
secondary patency with log-rank comparisons. Statistical
analysis also included 2 analysis and the Fisher exact test.
RESULTS
ELO occurred during the 7-year study period in 25
limbs in 22 patients, a patient incidence of 2.67%. Median
time to ELO was 34.9 days with the majority (60%) occur-
ring in the first 3 months. Median follow-up after ELO was
24.2  16.8 months. ELO occurred in both unsupported
unibody grafts (n  5, all Ancure) and supported modular
grafts (n 17; AneuRx, n 5; Zenith, n 9; Talent, n
2; Quantum, n  1). There were significant differences in
the occurrence of ELO in various graft designs (P  .024;
degrees of freedom, 6) (Table I). ELO in the Ancure graft
was most common, occurring in 5.12% of limbs.
Among grafts with ELO, the common iliac artery was
used as a landing zone for endograft limbs in 17 of 25
(68%) whereas the limb extended to the external iliac artery
in 8 of 25 limbs (32%). Among all grafts with a landing
zone in an iliac artery, 106 of 1620 (6.5%) were extended to
the external iliac artery. Thus, extension to the external iliac
artery was significantly more common in limbs that ulti-
mately presented with ELO (P  .001). Mean limb diam-
eter was 14.6 2.1 mm, with 12 of 25 limbs (48%) having
diameters less than 14 mm.
Presenting symptoms in the majority of cases were
severe rest pain and ischemia (68%). Claudication was the
presenting symptom in 16%, and 17% were identified by
examination in the perioperative period. Patients identified
in the perioperative period had signs or symptoms of severe
ischemia. All patients with severe ischemia had treatment
within 8 hours of presentation. Diagnosis of ELO was
made on the basis of physical examination alone in 7 of 25
(28%); physical examination and CT scan in 5 of 25 (20%);
Table I. Summary of graft types implanted and
occurrence of ELO with most commonly used grafts.
Differences between specific graft ELO rates were
statistically significant (P .024; df 6)
Graft
Grafts ELO
n % n %
Ancure 68 8.3 7 5.1
Aneurx 230 27.9 6 1.3
Excluder 30 3.6 0 0.0
Talent 39 4.7 2 2.6
Zenith 373 45.3 9 1.2
Quantum 22 2.7 1 2.3
Other* 61 7.4 0 0.0
Total 823 100 25 2.7
ELO, Endograft limb occlusion.
*Includes tube grafts, uni-iliac grafts, and grafts placed infrequently.physical examination and angiography in 10 of 25 (40%);
and physical examination, angiography, and CT scan in 3 of
25 (12%). In no instance was ELO managed conservatively.
There was no correlation between the landing zone of the
endograft limb and presenting symptoms.
Management of ELO was divided into 2 categories for
analysis. EVA was used in 12 of the 25 limbs (48%; 6
Zenith, 5 AneuRx, 1 Ancure), and EB was used in 12 (48%;
5 Ancure, 3 Zenith, 2 Talent, 1 AneuRx, 1 Quantum).
Selection of management was at the individual surgeon’s
discretion and preference. Arteriography was used in the
EB group only when the surgeon felt it was necessary for
diagnosis and perceived it would not delay appropriate
treatment.
The EVA consisted of balloon thrombectomy alone (n
 2; both AneuRx), Percutaneous angioplasty and stenting
(n 2; 1 Zenith, 1 Ancure), balloon thrombectomy along
with angioplasty and stenting (n 5; 3 Zenith, 2 AneuRx),
percutaneous Angiojet (Possis Medical, Minneapolis,
Minn) thrombectomy with stenting (n  1, Zenith), and
thrombolysis (n  2; 1 Zenith, 1 AneuRx) (Table II).
Balloon thrombectomy was not performed over a wire.
Only 3 EVAs were unsuccessful. One of these was an
incomplete balloon thrombectomy that was managed with
conversion to a femoral-femoral bypass. A second involved
an attempt at thrombolysis in which the wire could not be
completely passed through the occlusion. Thrombolytic
agent was infused for 4 hours, and when lack of progress
was confirmed with follow-up angiography, it was also
converted to femoral-femoral bypass. Finally, the second
thrombolysis case resulted in the only EVA perioperative
mortality (1/12, 8.3%), which was due to intracranial
hemorrhage. Balloon thrombectomy was used with a graft
limb with a landing zone in the common iliac artery 6 of 7
times. No method was employed to prevent embolization
to the internal iliac artery in these cases, and no emboliza-
tion to the internal iliac artery was observed. In the 2 EVAs






Thrombectomy  PTA and stent 5 20
Thrombectomy* 2 8
PTA  stent 2 8






Total 25 100 100
PTA, Percutaneous angioplasty.
*One case each of balloon thrombectomy and thrombolysis were unsuccess-
ful and converted to femoral-femoral bypass: One case of thrombolysis
resulted in death due to intracranial hemorrhage.
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complete occlusion of the limb; however, it was considered
a localized occlusion and no attempt at thrombectomy was
made. During evaluation, no EVA patients had an interven-
tion in the contralateral limb, and none went on to develop
a contralateral occlusion. One late failure occurred; this
patient had a decreased ankle brachial index noted in fol-
low-up that prompted repeat angiography along with an-
gioplasty and stenting distal to a prior stent for a native
external iliac artery stenosis. Nevertheless, none of the EVA
patients had recurrent ELO and none required amputation.
Importantly, EVA never resulted in graft dislodgement or
endoleak.
In contrast, EB were performed in 12 of 25 (48%)
limbs. In no case was EB unsuccessful in reestablishing limb
viability. Furthermore, there was no perioperative mortal-
ity. Only 3 of 12 patients in the EB group had preoperative
angiograms, and in 1 of these, angioplasty and stenting was
performed in the donor limb prior to femoral-femoral
bypass. This patient subsequently developed a donor limb
occlusion that was treated successfully with aortofemoral
bypass. The initial BP performed included femoral-femoral
bypass (n  11; 4 Ancure, 3 Zenith, 1 AneuRx, 1 Quan-
tum, 2 Talent), axillofemoral bypass (n  1, Ancure), and
aortofemoral bypass (n  1, Ancure) (Table II). Donor
limb occlusion was directly attributable to the need for
secondary procedure in 4 out of 6 (66.7%) EB failures.
These occurred in 3 Ancure and 1 AneuRx, all of which
landed in the common iliac artery. When donor limb oc-
clusion was the cause of bypass failure, the patients pre-
sented with severe bilateral lower extremity ischemia. This
was managed with an aortofemoral bypass (n  1), axil-
lofemoral bypass (n 1), open thrombectomy and stenting
of the donor limb followed by thrombectomy of the fem-
oral-femoral bypass (n  1), and open thrombectomy and
stenting of the donor limb followed by redo femoral-
femoral bypass (n  1). In the latter 2 cases, the cause of
donor limb thrombosis was identified as a limb stenosis.
The etiology of the 2 EB failures not associated with donor
limb occlusion was not identified. In the EB group, a total
of 2 of 12 patients (16.7%) proceeded to amputation due to
irreversible ischemia after revascularization. One of these
occurred after thrombectomy of a failed femoral-femoral
bypass and 1 after axillofemoral bypass for a failed femoral-
femoral bypass. There was no perioperative mortality with
EB.
At 12-month follow-up, freedom from secondary pro-
cedures with EVA was 80.2  17.7% versus 53.2  17.1%
with extraanatomic bypass (EB) (P  NS). Secondary
patency was 100% with EVA and 80.6 14.4% with EB (P
NS). There was no statistical significance between groups
in amputation and mortality rates.
DISCUSSION
Although EVAR results in clinical benefits to patients
with abdominal aortic aneurysms,2 the benefits come at the
price of an increased number of graft-related complications
and secondary procedures during follow-up. EVAR canresult in a 35% rate of secondary procedures at the end of 3
years.8
One of the more dramatic complications after EVAR,
ELO will often present with sudden onset of severe lower
extremity rest pain. In this series ELO occurred in 2.7% of
cases. This is more than the rate traditionally reported with
open aneurysm repair. In a review of 1047 open aneurysm
repairs at our institution for which there was long-term
follow-up, only 1 limb occlusion was identified.9 In the
Mayo Clinic experience, the risk of graft limb occlusion
after open aneurysm repair was reported at 2%.10 During
open aneurysm repair, the surgeon can take care to ensure
a straight unimpeded lie of the graft material. This is
impossible with EVAR. In addition, aneurysm remodeling
may create narrowing and/or occlusion of the endograft
limbs over time.
Several approaches have been advocated in the past for
management of ELO. Earlier series had higher rates of EB
whereas more recent case reports and series have advocated
EVA.3,4,6,7 One argument against an EVA and, in particu-
lar, against mechanical thrombectomy with balloon cathe-
ters is the theoretical risk of causing a graft dislodgement or
endoleak when this technique is performed in a modular
prosthesis. This argument was not validated by this series in
which no endoleak or graft dislodgement occurred despite
using EVA in modular graft designs.
As has been shown in previous reports, we found an
increased risk of ELO with unibody unsupported en-
dografts and extension of the endograft limb to the
external iliac artery.11-13 In fact, there were significant
differences in the occurrence of ELO, based on specific
graft type (Table I). Likewise, limbs were extended to
the external iliac artery in 32% of cases with ELO and
only 6.5% of all endograft limbs. One shortcoming of
identifying predisposing factors for ELO is the degree of
remodeling and aneurysm configuration change that fre-
quently occurs after EVAR. This series demonstrates that
many ELOs occur early after initial endograft deploy-
ment and may be more related to factors present at the
time of repair. Nevertheless, future aneurysm configura-
tion changes might result in development of ELO even
in previously ideal anatomy. ELO is a relatively rare event
and it is unlikely that one would withhold EVAR even in
a patient with predisposing risk factors. Such data may
potentially be used to help in future graft design or in
guiding adjunctive treatment at the time of EVAR. Be-
cause of the increased risk of graft limb occlusion with
unsupported grafts, commercially available grafts have
moved towards a dominance of the supported body
design, and while the Ancure graft was available, liberal
use of limb stents was advocated by some.6,7 The pur-
pose of this review was not to try to define additional risk
factors but rather to review the results of various man-
agement options.
This series has several limitations, including the small
population, retrospective design, potential for selection
bias in choosing management options, and potential
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reason, one must be cautious in using this data to make
specific recommendations regarding optimal manage-
ment of ELO. Nevertheless, we do believe some inter-
esting observations can be made from this study. First
among these is that EVA appears safe and appropriate in
the management of ELO. The theoretical disadvantages
of EVA—graft limb dislodgement, endoleak, or embo-
lism to the internal iliac arterywere not observed. In
addition, EB seemed to have a higher failure rate than
would be expected. This may be in part due to the donor
limb thrombosis that occurred in 4 of the EB patients,
which in turn may be related to the endograft rather than
a failure of EB. That is to say, the events leading to
ipsilateral ELO probably occurred in the contralateral
limb as well. Preoperative angiograms could possibly
have uncovered underlying stenoses in these donor limbs
and might have prevented future failure of EB. Although
ELO was diagnosed in the majority of cases without
angiography in this series, the extra time necessary for
the angiography may be worth its potential benefit,
especially if the angiography can be performed in the
operating room at the same time as revascularization.
Interestingly, in the 1 case of EB for which angiography
was performed and an underlying lesion treated, the
patient still went on to donor ELO. This suggests addi-
tional surveillance for progression to reocclusion may be
useful in treated limbs although the benefit of this is
unproven. Performing intraoperative pressure measure-
ments at the time of femoral-femoral bypass may also be
helpful in determining hemodynamically significant ste-
noses that the increased flow from the bypass might have
unmasked. Why the EVA had a lower rate of contralat-
eral ELO is uncertain. One possible explanation is that
the increased flow through the endograft limb after
femoral-femoral bypass resulted in more hemodynami-
cally significant lesions than when only 1 extremity was
supplied by the endograft limb.
Our data also suggest that EVA is possible in the
majority of patients. Of the 12 patients in whom we at-
tempted EVA, only 3 failures occurred, and 2 of these were
amenable to femoral-femoral bypass. The remaining pa-
tient did have a perioperative mortality in the EVA group
directly related to thrombolysis. This is in contrast to other
cases in which the physician found it difficult to pass a wire
through the occluded limb and hence tended to rely more
on femoral-femoral bypass.14 These data suggest an at-
tempt at EVA is warranted if it is the preference of the
operating surgeon.
Our experience with thrombolysis for ELO is small and
few if any conclusions can be drawn from it. Others have
had better success with thrombolysis for ELO.4 The ben-
efit of thrombolysis in selected patients is that it potentially
allows treatment of ELO through a purely percutaneous
approach. The Angiojet thrombectomy catheter along with
angioplasty and stenting was used in one case successfullyand also allows a purely percutaneous approach to the
ELO. Another approach that has been described uses suc-
tion thrombectomy combined with balloon thrombectomy
through a large sheath.3 ELO is a serious condition requir-
ing prompt treatment. A variety of approaches may be used
to treat ELO, and in large part the choice of treatment
should be individualized to the patient condition and the
skill set of the operating surgeon. EVA is an acceptable
alternative, whereas if EB is employed, assessment of the
donor limb and treatment of any underlying lesions may be
advisable.
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Volume 40, Number 3 Erzurum et al 423DISCUSSIONDr Ronald Fairman (Philadelphia, Pa). Your series is inter-
esting in that it’s really the first series that I’ve ever seen that’s
actually shown a higher incidence of limb occlusions in supported
grafts than in unsupported graft limbs. And it may just be that the
numbers are such that you did a great preponderance of supported
grafts as opposed to Ancure grafts in the series. But I think if you
could comment on that that would be very helpful.
I’m interested in knowing whether you managed acute limb
occlusions differently than you managed occlusions that would
have occurred, perhaps, after the 3-month window. So would you
take a different strategy if the limb occlusions were early post-op
versus late post-op?
How would you choose or select the interventions that you
would do? Would you always first try an endovascular approach
and, if that failed, would you then go to an extra-anatomic bypass?
How would you advise us in terms of individually selecting the
therapy for a graft limb occlusion?
I wasn’t sure, and I think I’m sure now, about why your
extra-anatomic bypass group had such a high failure rate. Clearly,
we’ve all had the impression that when doing extra-anatomic
bypasses in the presence of aneurysmal disease, the results are
better than for occlusive disease. Were all the failures due to donor
limb issues that were just unrecognized at the time of the extra-
anatomic bypass?
When do you think it’s preferable to use thrombolytic therapy
as an initial intervention? Do you think that’s ever actually a
preferred intervention to use early on? And did how the patients
present—whether they had rest pain, claudication, or, in fact, no
symptoms at all—influence kind of your initial treatment ap-
proach?
And lastly, although I know you mentioned that your goal was
not to identify factors that were predictive of graft limb occlusion,
I think perhaps that’s the thing that I’d be most interested in.
Could you identify any variables that in retrospect could tip you off
that a graft limb was going to go down—for example, issues of
angulated iliac arteries or perhaps graft limb oversizing in relation
to the size of the recipient iliac artery.
Dr Victor Z. Erzurum. As regards to your first question
concerning whether it’s more common in supported or unsup-
ported grafts, the rate of endograft limb occlusion was actually
highest with unsupported unibody grafts. In this group the rate of
endograft limb occlusion was 5.1% and this was statistically signif-
icant. It is true we had more endograft limb occlusions occur in
modular supported grafts but this is a reflection of the preponder-
ance of such grafts performed at our institution.Time after presentation did not seem to be a major criterion
for selection of specific management. Individual surgeons did tend
to have a preferred approach, but it was not time dependent. I do
think that the symptoms that the patient presented with tended to
influence management. As an example, the patients with severe
ischemia were much less likely to receive thrombolysis, and since a
substantial number of the patients had severe rest pain and severe
ischemia, this may be why we had few thrombolysis treatments.
With regard to your question about lytic therapy, I think
thrombolysis is a good option. I think that it is often not a
preferred treatment just because a majority of the patients do
present with fairly severe ischemia.
My approach at the present time with endograft limb occlu-
sion is to try an endovascular approach at first. Usually we start with
a left arm angiogram to get an idea of the anatomy, and either
proceed with trying to pass a wire through the limb at that time or
do a femoral cutdown and do a balloon thrombectomy followed by
stenting. If the endovascular approach is unsuccessful, we resort to
femoral-femoral bypass after ensuring the donor limb is free of
stenosis.
Four out of the 6 patients with extra-anatomic bypass failure
had a donor limb thrombosis. Why our extra-anatomic bypass
group had such a high failure rate is uncertain, especially with the
absence of angiograms. I think one of the problems with doing an
extra-anatomic bypass, at least a femoral-femoral bypass, is the risk
of donor limb occlusion, which relates to similar changes occurring
in both limbs. Donor limb thrombosis seemed to be an important
cause for the extra-anatomic bypass group failures. I think it would
be fairly easy to perform an angiogram prior to femoral-femoral
bypass. This may identify underlying lesions which could be
treated in the hopes of lowering the donor limb occlusion rate. The
presenting symptoms did not affect treatment except with regard
to thrombolytic therapy
As far as predictive factors of endograft limb occlusion, we did
find an increased risk of endograft limb occlusion with extension of
grafts to the external iliac artery. In addition, the risk appeared to
be graft specific, with the highest risk in unsupported unibody
grafts. Endograft limb occlusion is a fairly uncommon event, and it
is unlikely one would withhold aortic endografting even if a patient
had all of the previously identified risk factors. Additionally, even
with a patient having ideal anatomy, that anatomy might change
over time and result in endograft limb occlusion. So our concern
was, given that this is a rare event, not so much preventing it, but
how to manage it once it occurs.Authors requested to declare conditions of research funding
When sponsors are directly involved in research studies of drugs and devices, the editors will ask authors to clarify the
conditions under which the research project was supported by commercial firms, private foundations, or government.
Specifically, in the methods section, the authors should describe the roles of the study sponsor(s) and the
investigator(s) in (1) study design, (2) conduct of the study, (3) data collection, (4) data analysis, (5) data
interpretation, (6) writing of the report, and (7) the decision regarding where and when to submit the report for
publication. If the supporting source had no significant involvement in these aspects of the study, the authors should
so state.
